CA2314369A1 - Combinaison de prostaglandines e2/f2.alpha., destinee au traitement de l'impuissance et a l'accroissement de l'excitation sexuelle - Google Patents

Combinaison de prostaglandines e2/f2.alpha., destinee au traitement de l'impuissance et a l'accroissement de l'excitation sexuelle Download PDF

Info

Publication number
CA2314369A1
CA2314369A1 CA002314369A CA2314369A CA2314369A1 CA 2314369 A1 CA2314369 A1 CA 2314369A1 CA 002314369 A CA002314369 A CA 002314369A CA 2314369 A CA2314369 A CA 2314369A CA 2314369 A1 CA2314369 A1 CA 2314369A1
Authority
CA
Canada
Prior art keywords
pge2
prostaglandin
composition
pharmaceutically acceptable
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002314369A
Other languages
English (en)
Inventor
Nathan Earl Scott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/992,946 external-priority patent/US5981593A/en
Priority claimed from US09/038,378 external-priority patent/US5962528A/en
Application filed by Individual filed Critical Individual
Publication of CA2314369A1 publication Critical patent/CA2314369A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un procédé et une composition de traitement du dysfonctionnement érectile chez l'homme ou du dysfonctionnement de l'excitation sexuelle chez la femme, ce procédé comprenant les étapes consistant à administrer au patient une dose unitaire d'une formulation comprenant une dose efficace d'une prostaglandine, à savoir la prostaglandine E¿1?, la prostaglandine E¿2?, ou des sels ou dérivés de celles-ci, acceptables sur le plan pharmacologique, la prostaglandine étant formulée à l'aide d'une petite dose de prostaglandine F¿.alpha.2? et d'un milieu d'apport, acceptable sur le plan pharmacologique, et/ou d'un lubrifiant. Ce procédé concerne également la prostaglandine PGE¿2? formulée avec du mésylate de phentolamine, avec ou sans PGF¿2.alpha.?.
CA002314369A 1997-12-18 1998-12-15 Combinaison de prostaglandines e2/f2.alpha., destinee au traitement de l'impuissance et a l'accroissement de l'excitation sexuelle Abandoned CA2314369A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US08/992,946 1997-12-18
US08/992,946 US5981593A (en) 1991-07-03 1997-12-18 Prostaglandin E2 treatment of impotence
US508798A 1998-01-09 1998-01-09
US09/005,087 1998-01-09
US09/038,378 1998-03-11
US09/038,378 US5962528A (en) 1991-07-03 1998-03-11 Prostaglandin E2 /F2α combination for treating impotence
PCT/US1998/026609 WO1999030718A2 (fr) 1997-12-18 1998-12-15 COMBINAISON DE PROSTAGLANDINES E2/F2α, DESTINEE AU TRAITEMENT DE L'IMPUISSANCE ET A L'ACCROISSEMENT DE L'EXCITATION SEXUELLE

Publications (1)

Publication Number Publication Date
CA2314369A1 true CA2314369A1 (fr) 1999-06-24

Family

ID=27357802

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002314369A Abandoned CA2314369A1 (fr) 1997-12-18 1998-12-15 Combinaison de prostaglandines e2/f2.alpha., destinee au traitement de l'impuissance et a l'accroissement de l'excitation sexuelle

Country Status (5)

Country Link
EP (1) EP1059926A2 (fr)
CN (1) CN1282249A (fr)
AU (1) AU1827299A (fr)
CA (1) CA2314369A1 (fr)
WO (1) WO1999030718A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251436B1 (en) * 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US6825234B2 (en) 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
WO2000051978A1 (fr) 1999-03-01 2000-09-08 Nitromed, Inc. Prostaglandines nitrosees et nitrosylees, compositions et methodes d'utilisation
JP4834224B2 (ja) 1999-03-05 2011-12-14 デューク ユニバーシティ Ｃ１６不飽和ｆｐ−選択的プロスタグランジン類縁体
CA2362918A1 (fr) * 1999-03-08 2000-09-14 Elizabeth Stoner Procedes et compositions pour le traitement de la dyserection
IL139455A0 (en) * 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
ATE352300T1 (de) 2000-05-12 2007-02-15 Novalar Pharmaceuticals Inc Zusammensetzung bestehend aus phentolaminmesylat und deren verwendung
SE0100158D0 (sv) * 2001-01-19 2001-01-19 Synphora Ab Novel method and composition for local treatment of Meniere´s disease and tinnitus
CA2776429C (fr) * 2008-10-10 2019-07-23 Milux Holding S.A. Stimulation d'un tissu de la vulve sexuellement sensible
US9757330B2 (en) 2013-10-18 2017-09-12 Industrial Technology Research Institute Recipe for in-situ gel, and implant, drug delivery system formed thereby

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3917864A (en) * 1973-02-12 1975-11-04 Sultanali M M Karim Use of prostaglandins E and F for induction of labor
US4005221A (en) * 1974-04-01 1977-01-25 Karim Sultanali M M Use of prostaglandins to induce menstruation
US4311707A (en) * 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
SE463851B (sv) * 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
KR0169950B1 (ko) * 1990-04-25 1999-01-15 에드워드 엘. 멘델 발기 기능장애 치료용 제형, 어셈블리 및 조성물
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
AU2300092A (en) * 1991-07-03 1993-02-11 Nathan E. Scott Prostaglandin e2 treatment of impotence
US5482039A (en) * 1994-03-25 1996-01-09 Vivus, Inc. Process for diagnosing erectile dysfunction, and related methods of treatment

Also Published As

Publication number Publication date
WO1999030718A2 (fr) 1999-06-24
AU1827299A (en) 1999-07-05
EP1059926A2 (fr) 2000-12-20
WO1999030718A3 (fr) 1999-09-10
CN1282249A (zh) 2001-01-31

Similar Documents

Publication Publication Date Title
US5708031A (en) Prostaglandin E2 treatment of impotence
US5474535A (en) Dosage and inserter for treatment of erectile dysfunction
US9555168B2 (en) System for delivery of medication in treatment of disorders of the pelvis
CA2040914C (fr) Traitement des troubles de l'erection
AU701328B2 (en) Water-based topical cream containing nitroglycerin; method of preparation and use thereof
US6251436B1 (en) Drug preparations for treating sexual dysfunction
JP4544859B2 (ja) 男性勃起機能不全の治療のためのプロスタグランジン組成物
US6291528B1 (en) Prostaglandin E1/F2 in combination with prostaglandin F2α for enhancing female sexual arousal
CA2314369A1 (fr) Combinaison de prostaglandines e2/f2.alpha., destinee au traitement de l'impuissance et a l'accroissement de l'excitation sexuelle
EP1441770A1 (fr) Agents antidysrythmiques administres par voie vaginale utilises pour traiter les douleurs pelviennes et la sterilite
AU2002350644A1 (en) Vaginally administerd anti-dysrhythmic agents for treating pelvic pain and infertility
KR20000064392A (ko) 발기부전치료용pge-1함유동결건조된리포좀
US5962528A (en) Prostaglandin E2 /F2α combination for treating impotence
US5981593A (en) Prostaglandin E2 treatment of impotence
JPH101441A (ja) 局所麻酔組成物
US20030138494A1 (en) Drug preparations for treating sexual dysfunction
ES2326374T3 (es) Composiciones vaginales para el tratamiento de infecciones y traumas del tejido pelvico.
CA2243657C (fr) Composition pour le traitement de la dysfonction erectile
BR102016015716A2 (pt) Método, composição e kit para tratamento da disfunção erétil
Chien Medicated Intrauterine Devices: Development
TW200526229A (en) External preparation for treating sexual dysfunction

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued